University of Vigo

Pyridazin-3(2H)-one Derivatives as Selective Inhibitors of Monoamine Oxidase-B Isoform (MAO-B)

Posted by University of VigoResponsive · Patents for licensing · Spain

Summary of the technology

The pyridazine ring is a privileged fragment found in compounds with very different pharmacological properties, such as antihypertensive, antiplatelet, anti-inflammatory, antinociceptive, antidepressant, hypoglycemic, antiinfective or anticancer agents, many of them being pyridazin-3(2H)-one derivatives. The pyridazine ring is also included in polycyclic compounds acting as MAO-B inhibitors. However, simple pyridazin-3(2H)-one derivatives have not been described so far as selective MAO-B inhibitors.
The present invention provides novel pyridazin-3(2H)-one derivatives substituted at C4, C5 or C6 with several dithiocarbamate moieties that selectively inhibit the MAO-B activity and whose structure is unrelated to those currently available.

Description of the technology

This invention is concerned essentially with pyridazinone derivatives substituted at C4, C5 or C6 with dithiocarbamate fragments that are selective MAO-B inhibitors, and their use for the preparation of medicaments for treating disorders resulting from MAO-B hyperactivity, including neurodegenerative diseases, such as Parkinson´s and Alzheimer’s diseases and other dementias

Specifications

The present invention provides novel pyridazin-3(2H)-one derivatives substituted at C4, C5 or C6 with several dithiocarbamate moieties, linked by an alkyl chain of varying magnitude, that selectively inhibit the MAO-B activity and therefore useful for treating disorders resulting from MAO-B hyperactivity, including neurodegenerative diseases, such as Parkinson´s and Alzheimer’s diseases and other dementias.

Main advantages of its use

  • The novel pyridazin-3(2H)-one derivatives can be easily synthesized through a multi-component reaction, in which the appropriate 6(5)(4)-bromoalkyl analogue, an amine and carbon disulfide react in the presence of anhydrous potassium phosphate at room temperature. The compounds of the present invention were inactive against MAO-A. However, these simple pyridazinone derivatives are inhibitors MAO-B with IC50 values in the micromolar range.

Applications

  • The compounds of the present invention or their salts could be used by the pharmaceutical industry for the preparation of medicaments to treat disorders resulting from MAO-B hyperactivity, including neurodegenerative diseases, such as Parkinson´s and Alzheimer’s diseases and other dementias.

Related keywords

  • Pharmaceutics
  • Medicine, Human Health
  • Medical Research
  • Neurology, Brain Research
  • Pharmaceutical Products / Drugs
  • Medical/health
  • Pharmaceuticals/fine chemicals
  • Clinical Medicine
  • neurodegeneration
  • Parkinson’s disease
  • Pyridazin-3(2H)-one
  • dithiocarbamate
  • MAO-B
  • Alzheimer’s disease.

About University of Vigo

Technology Transfer Office from Spain

Public University

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.